Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients

Delia Mezzanzanica, Marina Fabbi, Marina Bagnoli, Samantha Staurengo, Marco Losa, Emanuela Balladore, Paola Alberti, Lara Lusa, Antonino Ditto, Silvano Ferrini, Marco A. Pierotti, Mattia Barbareschi, Silvana Pilotti, Silvana Canevari

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Purpose: Currently available clinicopathologic prognostic factors are imperfect predictors of clinical course in advanced-stage epithelial ovarian cancer patients. New molecular predictors are needed to identify patients with higher risk of relapse or death from disease. In a retrospective study, we investigated the prognostic impact of activated leukocyte cell adhesion molecule (ALCAM) expression in epithelial ovarian cancer. Experimental Design: We analyzed the effect of cell-anchorage loss on ALCAM cellular localization in vitro and assessed ALCAM expression by immunohistochemistry in a series of 109 well-characterized epithelial ovarian cancer patient samples. Chi-square test, Kaplan-Meier method, and Cox proportional hazard analyses were used to relate ALCAM cellular localization to clinical-pathologic parameters and to overall survival (OS) rate. Results: Loss of epithelial ovarian cancer cell anchoragewas associated both in vitro and in vivo with decreased ALCAM membrane expression. In vivo, ALCAM was localized to cell membrane in normal surface ovarian epithelium, whereas in 67% of the epithelial ovarian cancer samples, membrane localization was decreased or even lost, and the molecule was mainly expressed in cytoplasm. Median OS in this group of patients was 58 months, whereas a median OS was not yet reached in patients with ALCAM membrane localization (P = 0.036, hazard ratio [HR] = 2.0, 95% confidence interval [CI] 1.1 to 3.5). In a multivariate Cox regression model including all the available clinicopathologic variables, loss of ALCAM membrane expression was an independent factor of unfavorable prognosis (P = 0.042, HR = 2.15, 95% CI: 1.0 to 4.5). Conclusions: Decreased/lost ALCAM membrane expression is a marker of poorer outcome in epithelial ovarian cancer patients and might help to identify patients who could benefit from more frequent follow-up or alternative therapeutic modalities.

Original languageEnglish
Pages (from-to)1726-1733
Number of pages8
JournalClinical Cancer Research
Volume14
Issue number6
DOIs
Publication statusPublished - Mar 15 2008

Fingerprint

Activated-Leukocyte Cell Adhesion Molecule
Carcinoma
Survival
Membranes
Confidence Intervals
Chi-Square Distribution
Proportional Hazards Models
Ovarian epithelial cancer
Cytoplasm
Research Design
Survival Rate
Epithelium
Retrospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. / Mezzanzanica, Delia; Fabbi, Marina; Bagnoli, Marina; Staurengo, Samantha; Losa, Marco; Balladore, Emanuela; Alberti, Paola; Lusa, Lara; Ditto, Antonino; Ferrini, Silvano; Pierotti, Marco A.; Barbareschi, Mattia; Pilotti, Silvana; Canevari, Silvana.

In: Clinical Cancer Research, Vol. 14, No. 6, 15.03.2008, p. 1726-1733.

Research output: Contribution to journalArticle

Mezzanzanica, Delia ; Fabbi, Marina ; Bagnoli, Marina ; Staurengo, Samantha ; Losa, Marco ; Balladore, Emanuela ; Alberti, Paola ; Lusa, Lara ; Ditto, Antonino ; Ferrini, Silvano ; Pierotti, Marco A. ; Barbareschi, Mattia ; Pilotti, Silvana ; Canevari, Silvana. / Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 6. pp. 1726-1733.
@article{0bc36a1a1f174ea78d056571bb489da3,
title = "Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients",
abstract = "Purpose: Currently available clinicopathologic prognostic factors are imperfect predictors of clinical course in advanced-stage epithelial ovarian cancer patients. New molecular predictors are needed to identify patients with higher risk of relapse or death from disease. In a retrospective study, we investigated the prognostic impact of activated leukocyte cell adhesion molecule (ALCAM) expression in epithelial ovarian cancer. Experimental Design: We analyzed the effect of cell-anchorage loss on ALCAM cellular localization in vitro and assessed ALCAM expression by immunohistochemistry in a series of 109 well-characterized epithelial ovarian cancer patient samples. Chi-square test, Kaplan-Meier method, and Cox proportional hazard analyses were used to relate ALCAM cellular localization to clinical-pathologic parameters and to overall survival (OS) rate. Results: Loss of epithelial ovarian cancer cell anchoragewas associated both in vitro and in vivo with decreased ALCAM membrane expression. In vivo, ALCAM was localized to cell membrane in normal surface ovarian epithelium, whereas in 67{\%} of the epithelial ovarian cancer samples, membrane localization was decreased or even lost, and the molecule was mainly expressed in cytoplasm. Median OS in this group of patients was 58 months, whereas a median OS was not yet reached in patients with ALCAM membrane localization (P = 0.036, hazard ratio [HR] = 2.0, 95{\%} confidence interval [CI] 1.1 to 3.5). In a multivariate Cox regression model including all the available clinicopathologic variables, loss of ALCAM membrane expression was an independent factor of unfavorable prognosis (P = 0.042, HR = 2.15, 95{\%} CI: 1.0 to 4.5). Conclusions: Decreased/lost ALCAM membrane expression is a marker of poorer outcome in epithelial ovarian cancer patients and might help to identify patients who could benefit from more frequent follow-up or alternative therapeutic modalities.",
author = "Delia Mezzanzanica and Marina Fabbi and Marina Bagnoli and Samantha Staurengo and Marco Losa and Emanuela Balladore and Paola Alberti and Lara Lusa and Antonino Ditto and Silvano Ferrini and Pierotti, {Marco A.} and Mattia Barbareschi and Silvana Pilotti and Silvana Canevari",
year = "2008",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-07-0428",
language = "English",
volume = "14",
pages = "1726--1733",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients

AU - Mezzanzanica, Delia

AU - Fabbi, Marina

AU - Bagnoli, Marina

AU - Staurengo, Samantha

AU - Losa, Marco

AU - Balladore, Emanuela

AU - Alberti, Paola

AU - Lusa, Lara

AU - Ditto, Antonino

AU - Ferrini, Silvano

AU - Pierotti, Marco A.

AU - Barbareschi, Mattia

AU - Pilotti, Silvana

AU - Canevari, Silvana

PY - 2008/3/15

Y1 - 2008/3/15

N2 - Purpose: Currently available clinicopathologic prognostic factors are imperfect predictors of clinical course in advanced-stage epithelial ovarian cancer patients. New molecular predictors are needed to identify patients with higher risk of relapse or death from disease. In a retrospective study, we investigated the prognostic impact of activated leukocyte cell adhesion molecule (ALCAM) expression in epithelial ovarian cancer. Experimental Design: We analyzed the effect of cell-anchorage loss on ALCAM cellular localization in vitro and assessed ALCAM expression by immunohistochemistry in a series of 109 well-characterized epithelial ovarian cancer patient samples. Chi-square test, Kaplan-Meier method, and Cox proportional hazard analyses were used to relate ALCAM cellular localization to clinical-pathologic parameters and to overall survival (OS) rate. Results: Loss of epithelial ovarian cancer cell anchoragewas associated both in vitro and in vivo with decreased ALCAM membrane expression. In vivo, ALCAM was localized to cell membrane in normal surface ovarian epithelium, whereas in 67% of the epithelial ovarian cancer samples, membrane localization was decreased or even lost, and the molecule was mainly expressed in cytoplasm. Median OS in this group of patients was 58 months, whereas a median OS was not yet reached in patients with ALCAM membrane localization (P = 0.036, hazard ratio [HR] = 2.0, 95% confidence interval [CI] 1.1 to 3.5). In a multivariate Cox regression model including all the available clinicopathologic variables, loss of ALCAM membrane expression was an independent factor of unfavorable prognosis (P = 0.042, HR = 2.15, 95% CI: 1.0 to 4.5). Conclusions: Decreased/lost ALCAM membrane expression is a marker of poorer outcome in epithelial ovarian cancer patients and might help to identify patients who could benefit from more frequent follow-up or alternative therapeutic modalities.

AB - Purpose: Currently available clinicopathologic prognostic factors are imperfect predictors of clinical course in advanced-stage epithelial ovarian cancer patients. New molecular predictors are needed to identify patients with higher risk of relapse or death from disease. In a retrospective study, we investigated the prognostic impact of activated leukocyte cell adhesion molecule (ALCAM) expression in epithelial ovarian cancer. Experimental Design: We analyzed the effect of cell-anchorage loss on ALCAM cellular localization in vitro and assessed ALCAM expression by immunohistochemistry in a series of 109 well-characterized epithelial ovarian cancer patient samples. Chi-square test, Kaplan-Meier method, and Cox proportional hazard analyses were used to relate ALCAM cellular localization to clinical-pathologic parameters and to overall survival (OS) rate. Results: Loss of epithelial ovarian cancer cell anchoragewas associated both in vitro and in vivo with decreased ALCAM membrane expression. In vivo, ALCAM was localized to cell membrane in normal surface ovarian epithelium, whereas in 67% of the epithelial ovarian cancer samples, membrane localization was decreased or even lost, and the molecule was mainly expressed in cytoplasm. Median OS in this group of patients was 58 months, whereas a median OS was not yet reached in patients with ALCAM membrane localization (P = 0.036, hazard ratio [HR] = 2.0, 95% confidence interval [CI] 1.1 to 3.5). In a multivariate Cox regression model including all the available clinicopathologic variables, loss of ALCAM membrane expression was an independent factor of unfavorable prognosis (P = 0.042, HR = 2.15, 95% CI: 1.0 to 4.5). Conclusions: Decreased/lost ALCAM membrane expression is a marker of poorer outcome in epithelial ovarian cancer patients and might help to identify patients who could benefit from more frequent follow-up or alternative therapeutic modalities.

UR - http://www.scopus.com/inward/record.url?scp=37849052165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849052165&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0428

DO - 10.1158/1078-0432.CCR-07-0428

M3 - Article

C2 - 18347173

AN - SCOPUS:37849052165

VL - 14

SP - 1726

EP - 1733

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -